Abstract:
Systemic lupus erythematosus
(M32 according to ICD-10) is a systemic autoimmune
disease of unknown etiology, which is based on a
genetically determined violation of immune regulation,
which determines the formation of specific antibodies
to antigens of cell nuclei and immune complexes with
the development of immune inflammation in the
tissues of many organs [1,3 ,5, 6, 7, 10, 14, 16].
Hematological parameters are of great importance
in the diagnosis of SLE, especially in determining its
activity and the risk of progression. The hematological
manifestations observed in SLE can be represented by
both true autoimmune phenomena of autoimmune
hemolytic anemia (AHA), leukopenia (LP), and
thrombocytopenia
(TP),
as
well
as
cytopenic
syndromes
associated
with
the
use
of
immunosuppressive drugs. Currently, it is known that
hematological manifestations vary significantly in
severity and often do not require specific treatment,
with the exception of severe cytopenia, refractory to
glucocorticoids (GC) [3,11,15]; at the same time, their
significance as possible predictors of the further course
of SLE has not been sufficiently studied.
One of the causes of anemia in SLE is anemia of
chronic diseases (ACD), the cause of which is
considered to be a disorders of iron metabolism in the
macrophage
system
under
the
influence
of
inflammatory cytokines [2,4,5,8,9]. This type of
anemia in SLE is much less studied, although the
frequency of ACD in SLE varies from 11.9% to 37.1%.
[1,3,5,6,7]. There is practically no information about
the existence of iron deficiency anemia (IDA) in SLE,
although this type of anemic syndrome can occur in
these patients as well as in the general population. In
single studies, it is indicated that changes in the level
of serum ferritin and the content of bone marrow
sideroblasts are practically not informative in the
diagnosis of this type of anemia (Lila A.M., 2017).
